MEM Share Price Performance
AU$0.006
-0.00 (-14.27%)
2.0k% overvalued intrinsic discount
AU$0.00029
Fair Value
Price AU$0.006
Aadhvik AU$0.00029
Fair ValueAU$0.00029
Share Pricen/a
Memphasys Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
MEM Community Narratives
AA
Fair Value AU$0.00029 2.0k% overvalued intrinsic discount
Memphasys will witness revenue surge with promising growth
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Memphasys will witness revenue surge with promising growth
1) Catalysts — What Could Meaningfully Move Sales or Earnings? Regulatory & Commercial Milestones ✔ TGA Approval for Felix in Australia Memphasys recently received approval from the Therapeutic Goods Administration (TGA) in Australia for its Felix™ sperm separation system , enabling immediate commercial sales and deployment here — ahead of schedule.Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Trending Discussion
Recently Updated Narratives
AA
Memphasys will witness revenue surge with promising growth
Fair Value: AU$0.00029 2.0k% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Memphasys Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.0015
- 62.43%
- -2,074.59%
- 101.2%
About MEM
- Founded
- 2006
- Employees
- n/a
- CEO
- WebsiteView website
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
